Review


DOI :10.26650/JARHS2020-S1-0008   IUP :10.26650/JARHS2020-S1-0008    Full Text (PDF)

COVID-19 and Hemoglobinopathies

Ali FettahZeynep Karakaş

The novel coronavirus disease (COVID-19) was firstly reported at the end of 2019. The disease rapidly spread all around the world in a few months and was declared a worldwide pandemic by World Health Organisation in March 2020. COVID-19 causes respiratory tract illness that may generally occur as mild upper respiratory tract disease or pneumonia. Older patients and those with pre-existing medical conditions such as hypertension, diabetes, cardiovascular disease, cancer, chronic lung disease and chronic kidney disease have been identified as populations at risk of a severe disease course. Therefore, it is not clear how COVID-19 will progress in hemoglobinopathies such as sickle cell anemia and thalassemia, which are common comorbidity. In this review, it is planned to examine the condition of COVID-19, in which we still have limited information and remains unknown, in sickle cell anemia and thalassemia patients.

DOI :10.26650/JARHS2020-S1-0008   IUP :10.26650/JARHS2020-S1-0008    Full Text (PDF)

COVID-19 ve Hemoglobinopatiler

Ali FettahZeynep Karakaş

Yeni koronavirüs hastalığı (COVID-19) ilk olarak 2019'un sonunda bildirildi. Hastalık birkaç ay içinde hızla tüm dünyaya yayıldı ve Mart 2020'de Dünya Sağlık Örgütü tarafından dünya çapında bir salgın olarak ilan edildi. COVID-19 üst solunum yolu enfeksiyonu veya pnömoni gibi solunum yolu enfeksiyonlarına neden olan bir hastalıktır. İleri yaş grubunda ve altta yatan hipertansiyon, diabet, kardiyovasküler hastalık, kanser, kronik akciğer hastalığı, ve kronik böbrek hastalığı gibi komorbiditesi olanlar ağır hastalık tablosu için risk oluşturmaktadır. Bu yüzden orak hücreli anemi ve talasemi gibi sık komorbidite görülen hemoglobinopatilerde COVID-19'un nasıl seyredeceği net olarak bilinmemektedir. Bu derlemede halen kısıtlı bilgilere ulaşabildiğimiz ve bilinmezliği devam eden COVID-19’un orak hücreli anemi ve talasemi hastalarındaki durumunun irdelenmesi amaçlanmıştır.


PDF View

References

  • 1. T.C. Sağlık Bakanlığı (2020). COVID-19 (SARSCoV-2 Enfeksiyonu) Rehberi. Website: https:// covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_ Rehberi.pdf (erişim: 23.04.2020) google scholar
  • 2. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M .COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020 Apr 21;50(SI-1):620-632. google scholar
  • 3. Taher AT, Weatherall DJ, Capellini MD. Thalassaemia. Lancet 2018;391:155-67. google scholar
  • 4. Ricerca BM, Di Girolamo A, Rund D. Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications. Mediterr J Hematol Infect Dis. 2009 Dec 28;1(1):e2009028. google scholar
  • 5. Thalassaemia International Federation. The COVID-19 Pandemic and Haemoglobin Disorders. Website: https://thalassaemia.org.cy/wp-content/ uploads/2020/03/COVID-19-pandemic-andhaemoglobin-disorders_V3.pdf. (Accessed: 23.04.2020) google scholar
  • 6. British Society for Haematology. Advice on COVID-19 in patients with Sickle Cell Disease and Thalassaemia. Website: https://b-s-h.org.uk/media/18244/hbphccs-response-to-covid-v9-200420.pdf (Accessed: 23.04.2020) google scholar
  • 7. American Society of Hematology. COVID-19 and Thalassemia. Website: https://www.hematology. org/covid-19/covid-19-and-thalassemia (Accessed: 23.04.2020) google scholar
  • 8. European Hematology Association. Webinar Session 3: SCD/Thalassemia and COVİD-19. Possible Risks and a Proposal for a Patient Pathway During teh Pandemic. (Date 16 April 2020) google scholar
  • 9. Motta I, De Amicis MM, Pinto VM, Balocco M, Longo F, Bonetti F, et al. SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience. Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25840. [Epub ahead of print] google scholar
  • 10. Ünal S. Orak Hücreli Anemi Tedavi ve İzlem. Türk Hematoloji Derneği, Hematolog 2014:4-1. google scholar
  • 11. Abboud MR. Standard management of sickle cell disease complications. Hematol Oncol Stem Cell Ther. 2020 Mar 12. pii: S1658-3876(20) 30026-1. google scholar
  • 12. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561-73. google scholar
  • 13. Strouse JJ, Reller ME, Bundy DG, Amoako M, Cancio M, Han RN, et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood. 2010 Nov 4;116(18):3431-4. google scholar
  • 14. Bundy DG, Strouse JJ, Casella JF, Miller MR. Burden of influenza-related hospitalizations among children with sickle cell disease. Pediatrics. 2010 Feb;125(2):234-43. google scholar
  • 15. Beerkens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 2020 Apr 3. doi: 10.1002/ ajh.25809. [Epub ahead of print] google scholar
  • 16. Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020 Apr 8. doi: 10.1002/ajh.25821. [Epub ahead of print] google scholar
  • 17. De Luna G, Habibi A, Deux JF, Colard M, d’Alexandry d’Orengiani ALPH, Schlemmer F, et al. Rapid and Severe Covid-19 Pneumonia with Severe Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab. Am J Hematol. 2020 Apr 13. doi: 10.1002/ajh.25833. [Epub ahead of print] google scholar
  • 18. Secure SCD Registry. Surveillance Epidemiology of Coronavirus (COVID-19) Under Research European Exclusion. Website: https://covidsicklecell. org/ (Accessed: 23.04.2020) google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Fettah, A., & Karakaş, Z. (2020). COVID-19 and Hemoglobinopathies. Journal of Advanced Research in Health Sciences, 3(1), 63-67. https://doi.org/10.26650/JARHS2020-S1-0008


AMA

Fettah A, Karakaş Z. COVID-19 and Hemoglobinopathies. Journal of Advanced Research in Health Sciences. 2020;3(1):63-67. https://doi.org/10.26650/JARHS2020-S1-0008


ABNT

Fettah, A.; Karakaş, Z. COVID-19 and Hemoglobinopathies. Journal of Advanced Research in Health Sciences, [Publisher Location], v. 3, n. 1, p. 63-67, 2020.


Chicago: Author-Date Style

Fettah, Ali, and Zeynep Karakaş. 2020. “COVID-19 and Hemoglobinopathies.” Journal of Advanced Research in Health Sciences 3, no. 1: 63-67. https://doi.org/10.26650/JARHS2020-S1-0008


Chicago: Humanities Style

Fettah, Ali, and Zeynep Karakaş. COVID-19 and Hemoglobinopathies.” Journal of Advanced Research in Health Sciences 3, no. 1 (May. 2022): 63-67. https://doi.org/10.26650/JARHS2020-S1-0008


Harvard: Australian Style

Fettah, A & Karakaş, Z 2020, 'COVID-19 and Hemoglobinopathies', Journal of Advanced Research in Health Sciences, vol. 3, no. 1, pp. 63-67, viewed 26 May. 2022, https://doi.org/10.26650/JARHS2020-S1-0008


Harvard: Author-Date Style

Fettah, A. and Karakaş, Z. (2020) ‘COVID-19 and Hemoglobinopathies’, Journal of Advanced Research in Health Sciences, 3(1), pp. 63-67. https://doi.org/10.26650/JARHS2020-S1-0008 (26 May. 2022).


MLA

Fettah, Ali, and Zeynep Karakaş. COVID-19 and Hemoglobinopathies.” Journal of Advanced Research in Health Sciences, vol. 3, no. 1, 2020, pp. 63-67. [Database Container], https://doi.org/10.26650/JARHS2020-S1-0008


Vancouver

Fettah A, Karakaş Z. COVID-19 and Hemoglobinopathies. Journal of Advanced Research in Health Sciences [Internet]. 26 May. 2022 [cited 26 May. 2022];3(1):63-67. Available from: https://doi.org/10.26650/JARHS2020-S1-0008 doi: 10.26650/JARHS2020-S1-0008


ISNAD

Fettah, Ali - Karakaş, Zeynep. COVID-19 and Hemoglobinopathies”. Journal of Advanced Research in Health Sciences 3/1 (May. 2022): 63-67. https://doi.org/10.26650/JARHS2020-S1-0008



TIMELINE


Submitted24.04.2020
Accepted03.05.2020
Published Online15.05.2020

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.